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Complexes of IgA with FcRI/CD89 are not specific for pri- levels of macromolecular IgA, secondary to a primary
mary IgA nephropathy. mucosal hypoimmune response [5], and abnormal glyco-
Background. The presence of IgA together with the myeloid sylation [6–9] have been suggested to play a role. Also,IgA-receptor FcRI/CD89 in the circulation of patients with
a reduced clearance of IgA-IC by the mononuclear phago-IgA nephropathy (IgAN) has been suggested as a specific
cyte system, presumably due to saturation, reduction orpathogenic factor for mesangial deposition. However, in a re-
cent study we found these complexes also in serum samples altered function of IgA-receptors has been suggested
from healthy subjects. To investigate whether these circulating [10]. Until now, several IgA receptors or IgA-binding
complexes are specific for IgAN, the levels and characteristics molecules have been identified: the hepatic asialoglyco-of IgA-CD89 complexes were analyzed in patients with IgAN
protein receptor (ASPGR), the myeloid FcRI/CD89-and healthy controls.
receptor, the polymeric Ig-receptor (pIgR) on epithelialMethods. Specific ELISAs with different poly- and mono-
clonal antibodies and a sensitive dot-blot method were used cells in the mucosa, the Fc/-receptor on the majority
to measure IgA-CD89 levels in serum and purified IgA samples of B lymphocytes and macrophages, and the recently
obtained from healthy volunteers (N  30) and patients with described transferrin receptor [11–15]. In addition, twoIgAN (N 35). Fractionated samples of purified IgA were used
poorly-characterized IgA receptors have been reportedto compare the size characteristics of the IgA-CD89 complexes.
on various cell types [16–19]. The asialoglycoprotein re-Results. Almost all CD89 in serum of patients with IgAN
and controls was associated with high molecular weight IgA. ceptor and the myeloid IgA-receptor FcRI/CD89 are
Quantitative analysis of IgA-CD89 complexes in purified IgA thought to constitute the main receptors for the catabo-
revealed no significant difference between patients with IgAN lism of circulating IgA. There is indirect evidence forand controls. No correlation was found between levels of IgA-
impaired IgA clearance through the ASPGR-route [20],CD89 complexes and clinical parameters associated with pro-
gressive IgAN. and more recently, the FcRI/CD89-receptor has been
Conclusions. CD89 in the circulation is found mainly linked reported to play a crucial role in the clearance of IgA-
to high molecular weight IgA. The presence of these complexes complexes [20, 21]. CD89 has a higher affinity for large
is not specific for IgAN. Therefore, if IgA-CD89 complexes
molecular weight IgA as compared to monomeric IgAare involved in the pathogenesis of primary IgA nephropathy,
[22]. In addition, it was found that monomeric and di-additional factors are required to explain the IgA-CD89 com-
plex-mediated renal inflammation. meric IgA from patients have a reduced capacity to bind
recombinant CD89 [23].
The mechanism of IgA deposition in the renal mesan-
Primary IgA nephropathy, the most common form of gium remains unclear. Binding of IgA has been demon-
glomerulonephritis worldwide [1, 2], is characterized by strated to human mesangial cells [16], but no specific
the deposition of predominantly polymeric IgA of the receptor has been identified [19, 24–26]. The presence
IgA1-subclass in the glomerular mesangium [3, 4]. The of the FRI/CD89-receptor on mesangial cells was ex-
mechanism leading to renal deposition remains largely cluded by several groups [16, 19, 24, 27]. In addition, no
unknown, but overproduction of IgA1 with increased CD89 was detectable in deposits of IgA in the glomerular
mesangium of patients with IgAN [19] or in experimental
models [28]. After binding of IgA, myeloid cells canKey words: IgA nephropathy, macromolecular IgA, CD89, glomerulo-
nephritis, mesangial deposits, glycosylation, cytokines. release a soluble form of the FRI/CD89-receptor that
retains its ability to bind IgA [29]. Recently it was sug-Received for publication March 13, 2002
gested that complexes of IgA with CD89 deposit in miceand in revised form July 5, 2002
Accepted for publication September 6, 2002 kidneys and initiate an inflammatory reaction [28]. Fur-
ther, soluble FRI/CD89-IgA complexes were found 2003 by the International Society of Nephrology
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only in the circulation of patients with IgA nephropathy. For quantification of IgA in samples, ELISA wells
were coated with polyclonal rabbit--huIgA antibodyIn the same study, transgenic mice expressing human
(concentration 1g/mL; Dako, Glostrup, Denmark), fol-CD89 on monocytes/macrophages spontaneously devel-
lowed by serial twofold dilutions of samples for one houroped a clinical picture compatible with IgA nephropathy
at 37C. Bound IgA was subsequently detected by affinity[28]. However, in our very recent study, significant levels
purified biotin labeled goat F(ab)2 fragments directedof IgA-CD89 complexes also were found in healthy indi-
against IgA heavy chains (concentration 0.5 mg/mL, dilu-viduals [30]. The majority of the circulating CD89 was
tion 1/1000; Tago, Burlingame, CA, USA). Concentra-associated with high molecular weight IgA and was resis-
tions in samples were calculated relative to a knowntant to dissociation upon denaturation with sodium do-
standard of IgA that was included in each plate. Thedecyl sulfate (SDS). To evaluate these conflicting results,
detection limit of IgA was 2 ng/mL.we compared the levels and characteristics of IgA-CD89
For detection of IgA-CD89 complexes, a similarcomplexes in patients with IgAN and matched healthy
ELISA was used with monoclonal antibodies against thecontrols. The results indicate that equal amounts of IgA-
extracellular domain EC1 (2D11, 2H8) or EC2 (7D7,CD89 complexes are present both in patients and con-
A77) of CD89 (concentration 2 g/mL) or polyclonaltrols.
anti-CD89-antibodies (concentration 4 g/mL) as catch-
ing antibodies.
METHODS The presence of soluble CD89 and IgA-CD89 com-
plexes was analyzed in both serum and in polyethylene-Human subjects
glycol (PEG) 6000 (Merck-Schuchardt, Hohenbrunn, Ger-Thirty-five patients with biopsy confirmed IgAN were
many) precipitates of serum. For this purpose, 500 L ofincluded, defined by mesangial deposits of IgA as the
serum was precipitated with a final concentration of 6%dominant isotype. None of the patients had clinical or
(wt/vol) PEG 6000 and redissolved in 500 L phosphate-laboratory evidence of Henoch-Scho¨nlein purpura, sys-
buffered saline (PBS).temic lupus erythematosus, liver disease or received im-
munosuppressive therapy. In 20 patients with limited Affinity purification of IgA and gel-filtration
disease (13 males; mean age 46-years-old, range 30 to
IgA was purified by immunoabsorption as described66 years) kidney function was normal or moderately
previously [30]. In the fall through and eluate fractionsimpaired (serum creatinine 175 mol/L) and protein-
protein content was assessed by Pierce BCA Proteinuria 1.5 g/24 h. In 15 patients with advanced disease
Assay (Pierce, Munich, Germany) and IgA-concentra-
(13 males; mean age 42-years-old, range 19 to 62 years) tions were assessed by sandwich ELISA. Eluate fractions
kidney function was impaired (serum creatinine 175 containing IgA were pooled and frozen in aliquots at
mol/L) and/or proteinuria 1.5 g/24 h was present.
20C until further processing.
Clinical characteristics of both patient groups are sum- Affinity purified IgA, or total serum as a comparison,
marized in Table 1. As controls, 30 age- and sex-matched was separated by size on a 26/60 HR200 Superdex col-
healthy volunteers (20 males; mean age 44-years-old; umn and fractions were assessed for protein, IgA and
range 20 to 63 years) were recruited. Informed consent CD89 as described before [30].
was obtained from all subjects.
Western blot analysis
Detection of CD89, IgA and IgA-CD89-complexes
Recombinant soluble CD89, as well as serum, affinityby ELISA
purified IgA and fall through (non-binding proteins of
CD89 in serum was detected by enzyme-linked im- an IgA-immunoabsorbent) obtained from healthy indi-
munosorbent assay (ELISA) as described previously viduals and patients with IgAN, were separated on 6%
[30]. In short, several monoclonal antibodies against the SDS polyacrylamide gels under non-reducing conditions,
extracellular domain EC1 (2D11, 2H8) or EC2 (7D7, and blotted onto polyvinylidine difluoride (PVDF) mem-
A77) of CD89 (2 g/mL in coating buffer) [19, 31] or brane (Millipore, Bedford, MA, USA) as described be-
polyclonal antibodies against CD89 (4 g/mL) from rab- fore [30]. CD89 and IgA were detected with the mono-
bit origin were used as the catching antibodies. Purified clonal anti-CD89 antibody 7D7 (IgG1) at 10 g/mL and
recombinant CD89 was used as a standard and serum the monoclonal anti-IgA antibody 4E8 (IgG1) at 2
samples were tested in serial dilutions. Subsequently, g/mL, respectively [32]. Mouse monoclonal antibodies
CD89 was detected with digoxygenin (DIG)-conjugated were detected with HRP-conjugated goat-anti-mouse-
rabbit F(ab)2 anti-CD89 (1 g/mL), followed by horse- immunoglobulins (Dako).
radish peroxidase (HRP)-conjugated F(ab)2 anti-DIG.
Dot-blot assaysThe detection limit of recombinant CD89 was 50 pg/mL
both for the monoclonal antibody coating and polyclonal CD89-concentrations were also quantified by a dot-
blot assay as described before [30]. For this purposeantibody coating.
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50 L samples of affinity purified IgA or recombinant
CD89 were dotted in PBS onto PVDF-membranes using
a special dot-blot device (Bio-Rad, Herts, UK), ac-
cording to the manufacturer’s instructions. Membranes
were developed for CD89 reactivity with monoclonal
mouse-anti-CD89 (7D7) as described for Western blot-
ting. Dilutions of a standard recombinant CD89 solution
were included in each blot. The detection limit of rec-
CD89 was 1 ng/mL.
Statistical analysis
Statistical calculations were performed using the Stu-
dent t test.
RESULTS
Detection of CD89 and IgA-CD89 complexes
To quantify the amount of CD89 in serum of patients
with IgAN and healthy controls, we used different CD89-
specific ELISAs, based on monoclonal antibodies di-
rected against the EC1 or EC2 domain of CD89 or poly-
clonal antibodies against CD89 as coating and polyclonal
reagents of rabbit origin as the detecting antibodies.
RecCD89 could be detected in a dose dependent fashion
with a detection limit of 50 pg/mL in ELISAs using either
monoclonal or polyclonal anti-CD89 antibody coating
(Fig. 1A). In both control sera and in sera of patients
with IgAN, no significant levels of CD89 were detected.
In order to exclude the possibility that our ELISA system
was influenced by serum itself, a fixed concentration of
200 pg/mL recCD89 was added to dilutions of control
or patients serum and subsequently assessed for CD89.
This serum did not influence the detection of CD89
(Fig. 1B).
It has been suggested that CD89 can be found in PEG
precipitates of sera of patients with IgAN in complexed
form [28]. Therefore, CD89 concentrations were ana-
lyzed in PEG precipitates of normal and patient serum.
No increased levels of CD89 were found in these precipi-
tates, and the addition of CD89 to dilutions of PEG-
precipitates did not influence its detection (Fig. 1C).
Using an IgA-CD89-ELISA with monoclonal and poly-
clonal anti-CD89 as the catching antibodies, in sera and
PEG-precipitates of both patients with IgAN and con-
trols, no significant levels of IgA-CD89-complexes could
Fig. 1. Detection of circulating CD89 by ELISA. (A) Wells were coatedbe detected (data not shown). with a monoclonal antibody against CD89 (7D7), followed by a dose-
response of CD89 and detection of bound CD89 with polyclonal digoxy-
Presence of IgA-CD89 complexes in patients with genin conjugated anti-CD89. (B) At an input of 200 pg/mL recombinant
CD89 in buffer alone or in the presence of increasing concentrationsIgAN and controls
of normal () and patient () serum CD89 was measured in the above
In normal human serum CD89 is predominantly com- mentioned ELISA. Further, dose-responses of sera of a healthy control
() and a patient with IgAN () are shown. (C ) Control and patientplexed with IgA [30]. We analyzed for the presence of
serum was precipitated with PEG 6,000 in a final concentration ofCD89 and IgA using Western blot analysis in serum and 6%. Subsequently, CD89 was detected in the precipitates as described
affinity purified IgA, both from patients and controls. in panel B.
Under non-reducing conditions two main bands of IgA
were seen in both control and patient sera; representative
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Fig. 2. Circulating CD89 in complex with
IgA. (A) In Western blots of patient serum
(lane 1, 30 L of a dilution 1/300), control
serum (lane 2, 30 L of a dilution 1/300) and
recombinant CD89 (lane 3, 30 L of a concen-
tration of 60 ng/mL) were detected by mono-
clonal antibodies against IgA (4E8) and CD89
(7D7). (B) Purified IgA was obtained from
serum of a patient with IgAN by immunoabs-
orption. In Western blots of total serum (lane
1, 30 L of a dilution 1/300), purified IgA
(lane 2, 30 L) and fall through of the anti-
IgA affinity column (lane 3, 30 L) were de-
tected by monoclonal antibodies against IgA
(4E8) and CD89 (7D7). IgA and protein con-
centrations in respectively the purified IgA
and fall through were the same as in the start-
ing material.
2B). Both for patients and controls, similar results were
obtained with six individual sera for each group.
Quantitative isolation of IgA
The results above suggest that both in healthy subjects
and in patients with IgAN, CD89 is associated with IgA.
Therefore, we purified IgA from serum by affinity chro-
matography using anti-IgA-Sepharose. The results of
IgA isolation are illustrated by representative examples
of a healthy subject and a patient with IgA nephropathy.
Almost all IgA was bound to the immunoabsorbent and
could be eluted with acidic buffer both from the sera of
patients with IgAN and healthy controls (Fig. 3). IgA
was isolated in a similar way from the sera of all patients
with IgAN and healthy control subjects, followed by
quantification of the IgA concentrations in the eluates
and original sera. The recovery of IgA was comparable
in patients with IgAN and controls (92 	 5% and 94 	
5%, respectively). The average content of IgA in IgAN
was higher than in controls as reflected in the total
amount of IgA in the eluates (110 	 42 vs. 94 	 24 g
IgA).Fig. 3. Affinity purification of serum IgA. Fifty microliters of serum
of a control subject (A) and a patient with IgA nephropathy (B) were
diluted 20-fold and incubated with 1 mL packed Sepharose IgA-immu- Quantification of IgA-CD89 complexes
noabsorbent, left to rotate at 4C overnight and subsequently poured
in a small column. Bound IgA was eluted with acidic buffer and neu- In order to quantify the amount of CD89 in the affinity
tralized with Tris-HCl. In the fractions, protein () and IgA () were purified IgA preparations (thus, IgA-CD89 complexes),
assessed.
we developed a detection method for CD89. Because
we were only interested in IgA-CD89 complexes and
wanted to prevent disturbance of the assay by other
proteins, the IgA-CD89 complexes were quantified inexamples are shown in Figure 2A (left blot). CD89 was
affinity-purified IgA. Dot-blotting of a dose-response ofdetectable as a band of 180 kD and associated with the
recombinant CD89 and subsequent detection with mono-lower band of IgA (Fig. 2A, right blot). As a positive
clonal antibodies (7D7) revealed that CD89 could becontrol the previously described recombinant CD89 [29]
detected up to a limit of 10 ng/mL (Fig. 4). IgA-eluateswas visualized as a 30 kD band. When IgA was purified
from patients and controls in the same dot-blot assayfrom serum of a patient with IgAN by immunoabsorp-
also revealed a dose dependent relationship in the assaytion, bands of IgA and CD89 of similar size as that of
normals were seen in both serum and purified IgA (Fig. (Fig. 4).
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Fig. 4. Detection of recombinant CD89 by
dot-blot. Increasing concentrations of recom-
binant CD89 (A) or dilutions of affinity puri-
fied IgA from a control or a patient with IgAN
(B) were dotted onto PVDF membranes and
developed for CD89-reactivity. The number
of pixels was counted with densitometry. In
all cases a linear dose-dependent response of
detectable CD89 was found.
IgA-CD89 complexes in patients with IgAN and
healthy controls
Affinity purified IgA from patients with IgA nephrop-
athy and controls was assessed for IgA and CD89. IgA
concentrations were determined using ELISA and CD89
by dot-blot assay. In normals the CD89 concentrations
were 161	 56 ng/mL and there were no significant differ-
ences in the two patient groups (150 	 28 and 152 	
26 ng/mL). Using the recovery percentages of the IgA
isolation procedure for each sample, as mentioned ear-
lier in this article, the calculated serum levels of CD89
were 24.2	 8.5g/mL for normals and 22.6	 4.2g/mL
and 22.9	 4.0 g/mL for the two patient groups, respec-
tively. Calculated concentrations of CD89 and CD89 per
g IgA were not significantly different in the patient
group and the healthy controls (P  0.41 and 0.30, re-
spectively; Fig. 5). On a weight basis, the CD89/IgA ratio
was 1.1% and 1.0% for the control and patient group,
respectively. On a molar basis this was 6,6% and 6.0%,
respectively, which indicates that about 6 to 7% of the
circulating IgA contains CD89.
Proteinuria and impaired renal function are risk fac-
tors for progressive disease in IgA nephropathy. Based
on renal function and proteinuria, patients were divided
in groups with limited and advanced disease (Table 1).
No significant differences of CD89 (P  0.83) and CD89
per g IgA (P  0.10) were found between the both
groups of patients with IgAN (Fig. 5).
Isolation of IgA has no effect on size distribution
Fig. 5. CD89 concentrations in serum from controls and patients withIt is possible that the affinity isolation procedure may
IgAN. (A) Using the recovery percentages of the isolation procedure,affect the size of the isolated IgA as compared to that
levels of CD89 were calculated in serum from controls and two groups
in whole serum. Therefore, 2 mL serum from a healthy of patients with IgAN: patients with limited disease (creatinine 175
mol and proteinuria 1.5 g/24 h) and patients with advanced diseaseindividual as well as affinity purified IgA were fraction-
(creatinine 175 mol and/or proteinuria 1.5 g/24 h). (B) In affinityated by size using gel filtration, and then assessed for
purified IgA of the same groups, concentrations of IgA were measured
IgA by ELISA and for protein by Pierce. The results by ELISA and subsequently the CD89/IgA weight ratios were calculated
for each individual.illustrate for one representative subject that no signifi-
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Table 1. Clinical characteristics of patients with IgA nephropathy
Limited disease Advanced disease
Median Range Median Range P value
Creatinine lmol/L 107 77–169 275 82–1500 
0.01
Erythrocyturia 100% 100% NS
Urinary protein g/24 h 0.48 0.08–1.48 1.86 0.15–5.18 
0.01
Systolic blood pressure mm Hg 128 105160 130 110–160 NS
Diastolic blood pressure mm Hg 80 55100 85 70–98 NS
Number of antihypertensives 1 0–1 1 0–3 NS
NS is not significant. In the patient group with limited disease, serum creatinine was lower than 175 mol/L and proteinuria less than 1.5 g/24 h. In the patient
group with advanced disease, creatinine was higher than 175 mol/L and/or proteinuria of more than 1.5 g/24 h was present.
Fig. 7. Size distribution of CD89 in IgA eluates from a control andFig. 6. Gel-filtration on Superdex HR200 of normal serum and affinity
patient with IgAN. Affinity purified IgA samples from a control (A)purified IgA. (A) Two milliliters of serum of a healthy control was
and patient with IgAN (B) were separated by size on Superdex HR200.fractionated by gel-filtration and assessed for protein () and IgA ().
Fractions were assessed for CD89 using dot-blot assay () and IgA(B) IgA from 2 mL of the same control subject was purified by affinity
using ELISA ().chromatography and subsequently fractionated and analyzed for pro-
tein and IgA as described above. No significant difference between
filtration profile of IgA in serum and purified IgA was found.
meric state [30]. In order to investigate the size distribu-
tion of CD89 in affinity purified IgA from patients with
cant shift in size distribution of IgA occurs in the affinity IgAN, purified IgA was fractionated by gel-filtration and
isolation procedure relative to that in untreated serum. assessed for IgA by ELISA and CD89 by dot-blot assay.
Further, the IgA and protein profile in the affinity puri- The results indicate that CD89 both in patients with
fied IgA exhibited an overlap, suggesting that IgA was IgAN and controls is associated with high molecular
the major protein present in the purified samples (Fig. weight IgA (Fig. 7). More than 80% of the IgA-associ-
6). Similar results were obtained with the sera and iso- ated CD89 was found in the fractions containing high
lated IgA from six patients with IgAN and six controls. molecular weight IgA.
Size distribution of IgA-CD89 complexes in
purified IgA DISCUSSION
Recently, we have shown that covalently bound IgA- The present study demonstrates that IgA-CD89 com-
plexes are present in serum of patients with IgA ne-CD89 complexes in human serum circulate in a poly-
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phropathy and healthy subjects. After affinity purifica- 25 g/mL) and the absence of ELISA reactivity. In an
earlier study, low levels of circulating IgA-CD89 com-tion, the relative recovery of IgA from the sera of both
groups was similar and the isolation procedure did not plexes were found by ELISA exclusively in patients with
IgAN [28]. Since under these conditions covalent com-significantly affect the size distribution of IgA. CD89
was found associated with high molecular weight IgA plexes are most likely not detected, this might represent
other forms of IgA-CD89 complexes.and IgA-CD89 levels were comparable in both groups.
These results do not support the hypothesis that circulat- In summary, our results indicate that the presence of
IgA-CD89 complexes in the circulation alone is insuffi-ing IgA-CD89 complexes are specific for patients with
IgA nephropathy. cient to explain mesangial deposition of IgA in patients
with IgAN. Apparently other factors such as local cyto-IgA-CD89 complexes have been suggested to play a
role in the pathogenesis of primary IgA nephropathy. kine production, altered glycosylation [6–9] or expres-
sion of as yet undefined IgA receptors are required inThese complexes were found mainly in serum of patients
with IgAN. In the same study transfer of serum from addition to the presence of IgA- or IgA-CD89 complexes
in the mesangial deposits.CD89 transgenic mice to controls led to rapid mesangial
deposition of IgA [28]. However, recently we found that
Reprint requests to P.J.M. van der Boog, M.D., Department of Ne-
CD89 is present in the circulation of healthy human phrology, C3-P, Leiden University Medical Center, PO Box 9600, 2300
RC Leiden, The Netherlands.subjects [30]. To investigate the specificity of IgA-CD89
E-mail: p.j.m.van_der_boog@lumc.nlcomplexes for IgA nephropathy, we analyzed the pres-
ence and size characteristics of IgA-CD89 complexes in
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